Source comparison
MK-677 for Bone Health Research Evidence: Comparison
Mechanism Ghrelin receptor agonist → pulsatile GH release → sustained IGF-1 elevation + direct GHSR1a activation in bone Exogenous GH → IGF-1 elevation (suppresses endogenous GH via negative feedback) Inhibits osteoclast-mediated bone resorption (no anabolic e
This comparison does not assign a generated winner or score.
- Mechanism
- Ghrelin receptor agonist → pulsatile GH release → sustained IGF-1 elevation + direct GHSR1a activation in bone
- Exogenous GH → IGF-1 elevation (suppresses endogenous GH via negative feedback)
- Inhibits osteoclast-mediated bone resorption (no anabolic effect)
- MK-677 preserves endogenous GH pulsatility; bisphosphonates stop bone loss but don't build new bone
- Route
- Oral (25mg daily typical research dose)
- Subcutaneous injection (0.3–0.6mg/kg weekly)
- Oral (10mg weekly for alendronate)
- MK-677 offers oral bioavailability without injection burden
- IGF-1 Elevation
- 60–90% sustained increase over 12 months
- 100–200% acute increase (dose-dependent)
- No effect on IGF-1
- MK-677 sustains elevation without tachyphylaxis; exogenous GH shows higher peaks but variable troughs
- BMD Impact (Human Trials)
- +2.7% lumbar spine, +1.8% femoral neck at 12 months
- +4–6% at spine/hip over 18 months (elderly cohorts)
- +5–8% at spine over 3 years (postmenopausal women)
- Bisphosphonates show largest BMD gains; MK-677 effect size is modest but includes anabolic signaling
- Fracture Data
- Not established in humans (animal models show 40% faster healing)
- Reduces fracture incidence by 30–40% in GH-deficient adults
- Reduces vertebral fracture risk by 50% in osteoporosis trials
- MK-677 lacks fracture outcome data; bisphosphonates have strongest clinical evidence for fracture prevention
- Professional Assessment
- Best suited for research exploring anabolic bone pathways and fracture healing acceleration. Not a replacement for anti-resorptive therapies in clinical osteoporosis management
- GH is effective but requires injection and carries metabolic side effects (insulin resistance, edema); MK-677 may offer a more tolerable alternative for bone anabolism research
- Bisphosphonates are first-line for osteoporosis but lack regenerative capacity; MK-677 targets different biology. Formation rather than resorption inhibition